Sichenzia Ross Ference LLP Represents Laidlaw & Company (UK) Ltd. in $5.75 Million Public Offering and Nasdaq Uplisting of Silo Pharma, Inc.
Press Release – New York, NY – October 3, 2020 – Sichenzia Ross Ference LLP announced today that it represented Laidlaw & Company (UK) Ltd. in the $5.75 million initial public offering and Nasdaq uplisting of Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. 1,150,000 shares of common stock, which included the full exercise of the underwriters’ over-allotment option, were sold to the public at a price of $5.00 per share. Silo Pharma’s common stock began trading on the Nasdaq Capital Market under the ticker symbol “SILO” on September 27, 2022.
Laidlaw & Company (UK) Ltd. acted as the sole book-running manager for the offering. The Benchmark Company, LLC acted as the co-manager for the offering.
The Sichenzia Ross Ference LLP team was led by partners Michael Ference and Barrett DiPaolo and associates Matt Siracusa and Kayla Scoccola.
- Sichenzia Ross Ference Carmel LLP represents BriaCell Therapeutics in $5.5 Million Public Offering - December 12, 2024
- Sichenzia Ross Ference Carmel LLP Represents New Era Helium in De-SPAC Transaction, Nasdaq Listing and up to $85 Million in Financing - December 9, 2024
- Sichenzia Ross Ference Carmel LLP represents Madison Global Partners, LLC in an Unsecured Senior Convertible Note and Warrant Offering up to $1 Million - December 6, 2024